RFG Advisory LLC Makes New $27.33 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

RFG Advisory LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, HoldingsChannel reports. The institutional investor bought 2,870,700 shares of the biotechnology company’s stock, valued at approximately $27,329,000. BioCryst Pharmaceuticals comprises 0.5% of RFG Advisory LLC’s holdings, making the stock its 26th biggest holding.

A number of other large investors have also recently modified their holdings of the company. Royal Bank of Canada grew its stake in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in BioCryst Pharmaceuticals by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. raised its position in BioCryst Pharmaceuticals by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after purchasing an additional 640,704 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after buying an additional 47,355 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $9.97 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $10.32. The business has a fifty day moving average price of $8.88 and a 200 day moving average price of $8.23. The stock has a market capitalization of $2.53 billion, a P/E ratio of -5.60 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Citizens Jmp boosted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.